Entrada Therapeutics (TRDA) Net Cash Flow (2020 - 2026)

Entrada Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$14.6 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 56.23% year-over-year to -$14.6 million in Q1 2026; TTM through Mar 2026 was $7.9 million, a 1427.05% increase from a year earlier, with the FY2025 full-year figure at -$10.8 million, down 132.18% from the prior year.
• Net Cash Flow declined to -$14.6 million in Q1 2026 per TRDA's latest filing, from -$2.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $182.5 million in Q1 2023 and bottomed at -$202.5 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$2.9 million (2025), against an average of -$12.4 million.
• Across the five-year window, Net Cash Flow surged 292.79% in 2023 and slumped 4101.68% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$8.2 million in 2022, then jumped by 292.79% to $15.7 million in 2023, then soared by 47.34% to $23.2 million in 2024, then sank by 112.49% to -$2.9 million in 2025, then sank by 405.12% to -$14.6 million in 2026.
• Per Business Quant, the three latest TRDA Net Cash Flow figures stand at -$14.6 million (Q1 2026), -$2.9 million (Q4 2025), and $20.8 million (Q3 2025).